Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments

Merav Bar, MD
Published: Thursday, Jan 02, 2014
Seattle Cancer Care AllianceDr. Merav Bar
Merav Bar, MD
Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center

Assistant Professor, Medical Oncology Division, University of Washington

Seattle Cancer Care AllianceSeattle Cancer Care Alliance
Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers. These new T-cell therapies are primarily being tested in clinical trials involving patients with highrisk leukemia or lymphoma before or after bone marrow transplant (BMT).

Preventing Relapse in Adults After Allogeneic BMT for Lymphoid Malignancies Approved by the FDA last year, CD19-specific Donor T Cells for B-Cell Malignancies After Allogeneic Transplant is a phase I/II trial designed to boost the graft-versus-tumor effect in subgroups of adults with acute lymphocytic leukemia, chronic lymphocytic leukemia, or diffuse large B-cell lymphoma who have received an allogeneic BMT from a matched related donor, thereby reducing the risk of posttransplant relapse.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication